CUREVAC

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

CUREVAC

Social Links:

Facebook

Twitter

Industry:

Biopharma Biotechnology Therapeutics

Founded:

2000-01-01

Address:

Tübingen, Baden-Wurttemberg, Germany

Country:

Germany

Website Url:

http://www.curevac.com

Total Employee:

251+

Status:

Active

Contact:

+49707198830

Email Addresses:

[email protected]

Total Funding:

1.85 B USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network

Similar Organizations

chiasma-logo

Chiasma

Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.

Current Advisors List

wolfgang-hartwig_image

Wolfgang Hartwig Board of Directors @ CureVac
Board_member

daniel-l-menichella_image

Daniel L. Menichella Chairman of the Executive Board @ CureVac
Board_member

christof-hettich_image

Christof Hettich Member of the Board of Directors @ CureVac
Board_member

craig-tooman_image

Craig Tooman Member Of The Supervisory Board @ CureVac
Board_member
2019-06-01

mathias-hothum_image

Mathias Hothum Board Member @ CureVac
Board_member

friedrich-bohlen_image

Friedrich Bohlen Chairman of the Board of Directors @ CureVac
Board_member

ingmar-hoerr_image

Ingmar Hoerr Chairman Of The Supervisory Board @ CureVac
Board_member

Current Employees Featured

franz-werner-haas_image

Franz-Werner Haas
Franz-Werner Haas Chief Corporate Officer @ CureVac
Chief Corporate Officer
2012-01-01

florian-von-der-mulbe_image

Florian von der Mulbe
Florian von der Mulbe Co-Founder, CPO @ CureVac
Co-Founder, CPO
2018-01-01

ulrike-gnad-vogt_image

Ulrike Gnad-Vogt
Ulrike Gnad-Vogt Chief Medical Officer @ CureVac
Chief Medical Officer
2013-08-01

nigel-horscroft_image

Nigel Horscroft
Nigel Horscroft Area Head - Molecular Therapy @ CureVac
Area Head - Molecular Therapy
2017-01-01

mariola-fotin-mleczek_image

Mariola Fotin-Mleczek
Mariola Fotin-Mleczek Chief Technology Officer @ CureVac
Chief Technology Officer
2018-10-01

george-siber_image

George Siber
George Siber Member of SAB @ CureVac
Member of SAB
2015-01-01

patrick-baumhof_image

Patrick Baumhof
Patrick Baumhof Vice President Formulation & Delivery @ CureVac
Vice President Formulation & Delivery
2017-01-01

pierre-kemula_image

Pierre Kemula
Pierre Kemula CFO @ CureVac
CFO
2016-10-01

steve-pascolo_image

Steve Pascolo
Steve Pascolo Co-Founder and CSO @ CureVac
Co-Founder and CSO
2000-05-01

regina-heidenreich_image

Regina Heidenreich
Regina Heidenreich Head of Immunotherapy @ CureVac
Head of Immunotherapy
2012-12-01

Founder

florian-von-der-mulbe_image

Florian von der Mulbe

ingmar-hoerr_image

Ingmar Hoerr

steve-pascolo_image

Steve Pascolo

Stock Details

Company's stock symbol is NASDAQ:CVAC

Acquisitions List

Date	Company	Article	Price
2022-06-08	Frame Cancer Therapeutics	Frame Cancer Therapeutics acquired by CureVac	32 M EUR

Investors List

german-federal-ministry-of-education-and-research-bmbf_image

Key Employee Changes

Date	New article
2020-08-04	Curevac names Franz-Werner Haas as CEO

Official Site Inspections

http://www.curevac.com Semrush global rank: 241.55 K Semrush visits lastest month: 291.99 K

Host Informations
Whois Informations

Loading ...